This is a nicely detailed summary of an investor conference, with all the other Hemispherx programs (flu, cancer) excerpted out. http://www.facebook.com/note.php?note_id=469940716796&comments&ref=mf One additional thing that was said on Tuesday, the 16th, during a Quarterly conference call and that relates directly to the slide 12 bar graph in the link above -- is that Hemispherx thinks they have a therapeutic surrogate marker for XMRV->CFS. IOW, patients that test positive, respond best. WPI is culturing their 516 trial participants and they only have about 10-15% of the data they want. They figure they need 60-85% of the data to approach the FDA again. A peer reviewed CFS/QT interval paper should be published very soon.